Rafael Mimbela
Neurodevelopmental Disabilities · Donna, TXNPI 1730296047
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 628 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,538 and has fallen 56.0% since, to $1,117 in 2025.
Across 628 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Ironshore Pharmaceuticals Inc.$1K
- Neurelis, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Corium, LLC$640
- Sunovion Pharmaceuticals Inc.$418
- plus $2K from 17 others
What the payments were for
- Food & beverage$9,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 106 | $2,003 |
| Ironshore Pharmaceuticals Inc. | 63 | $1,449 |
| Neurelis, Inc. | 40 | $1,380 |
| Supernus Pharmaceuticals, Inc. | 110 | $1,254 |
| Corium, LLC | 42 | $640 |
| Sunovion Pharmaceuticals Inc. | 104 | $418 |
| Sumitomo Pharma America, Inc. | 63 | $381 |
| Collegium Pharmaceutical, Inc. | 14 | $353 |
| Jazz Pharmaceuticals Inc. | 19 | $319 |
| Eisai Inc. | 21 | $319 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $211 |
| Otter Pharmaceuticals, LLC | 6 | $161 |
| Catalyst Pharmaceuticals, Inc. | 7 | $133 |
| SK Life Science, Inc. | 6 | $126 |
| Biogen | 1 | $120 |
| Livanova USA, Inc. | 2 | $77 |
| Biocodex, Inc. | 2 | $54 |
| Tris Pharma Inc | 2 | $52 |
| Aquestive Therapeutics, Inc. | 2 | $39 |
| Nobelpharma America, LLC | 1 | $38 |
| Immedica Pharma US, Inc. | 1 | $24 |
| Biomarin Pharmaceutical Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neurodevelopmental disabilities providers in Texasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 37 | $4,467 |
| Carbamazepine | 13 | $767 |
| Levetiracetam | 32 | $584 |
| Topiramate | 37 | $107 |
Paid to pharmacies, not to this prescriber.
Other neurodevelopmental disabilities in Donna
- Satish AgadiGalveston$8K
- Rafael Villalobos-NietoHarlingen$8K
- Saeed KahkeshaniBaytown$3K
- Uloma LabrieDallas$2K
- Pamela LupoWebster$2K
- Linda NguyenDallas$526
- Vanessa Caress Mbanga TchakountePasadena$319
- Katrina Willie-MusomaMansfield$172
- Pauline FilipekHouston$168
- Sangeeta ElhenceFort Worth$100
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.